ruxoprubart + eculizumab

This agent is a combination of **ruxoprubart** (formerly NM8074) and **eculizumab**. Ruxoprubart is a humanized monoclonal antibody targeting the Bb domain of complement factor B, thus blocking the alternative pathway of complement activation while sparing the classical pathway. Eculizumab is a monoclonal antibody that inhibits terminal complement protein C5, preventing the formation of the membrane attack complex. The combination is being investigated for **paroxysmal nocturnal hemoglobinuria (PNH)**, particularly in patients with inadequate response to eculizumab monotherapy. The rationale is that blocking both factor B (upstream in the alternative pathway) and C5 (terminal pathway) may provide greater control of complement-mediated hemolysis and associated symptoms[1][2][5].

Other names

anti-factor Bb monoclonal antibody NM8074 + eculizumab